SuperworthActinium Pharmaceuticals EPS ATNM
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- $0.36
- Latest quarter, Q2 FY26
- $0.89
- Fiscal year 2025
- −$1.08
Actinium Pharmaceuticals' earnings per share was $0.36 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.89.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.08 | n/a |
| FY2024 | −$1.27 | n/a |
| FY2023 | −$1.84 | n/a |
| FY2022 | −$1.36 | n/a |
| FY2021 | −$1.20 | n/a |
| FY2020 | −$2.15 | n/a |
| FY2019 | −$4.55 | n/a |
| FY2018 | −$6.90 | n/a |
| FY2017 | −$12.30 | n/a |
| FY2016 | −$15.00 | n/a |
| FY2015 | −$16.50 | n/a |
| FY2014 | −$28.50 | n/a |
| FY2013 | −$14.10 | n/a |
| FY2012 | −$160.80 | n/a |
| FY2011 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.89 | n/a | $0.36 | |
| Q1 FY26 | −$0.18 | n/a | −$0.75 | |
| Q4 FY25 | −$0.19 | n/a | −$1.08 | |
| Q3 FY25 | −$0.16 | n/a | −$1.10 | |
| Q2 FY25 | −$0.22 | n/a | −$1.31 | |
| Q1 FY25 | −$0.51 | n/a | −$1.47 | |
| Q4 FY24 | −$0.21 | n/a | −$1.27 | |
| Q3 FY24 | −$0.37 | n/a | −$1.40 | |
| Q2 FY24 | −$0.38 | n/a | −$1.52 | |
| Q1 FY24 | −$0.31 | n/a | −$1.72 | |
| Q4 FY23 | −$0.34 | n/a | −$1.84 | |
| Q3 FY23 | −$0.49 | n/a | −$1.92 |
Against its peers
Companies in Drug Manufacturers - General nearest Actinium Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.28 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Actinium Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.